Cabaletta Bio, Inc. CABA
1.30 USD +0.02 (+1.56%)
At closeNov 9, 2026, 4:47 AM EST
1.44 +0.14 +10.79%
Pre-market · Nov 9, 4:47 AM ET
1.25 Day range 1.33
1.18 52-week range 4.23
- YTD
- -40.64%
- 1 year
- -47.58%
News
benzinga.com Cabaletta Bio Q3 EPS $(0.28) Beats $(0.33) Estimate Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.33) by 15.15 percent. This is a 36.36 percent increase over losses of…
globenewswire.com Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update RESET-Myositis ® registrational adult topline results anticipated in 2H27 with BLA submission in 1Q28, including Phase 1/2 juvenile dermatomyositis data for potential PRV eligibility and Phase 1/2…
globenewswire.com Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PHILADELPHIA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies…
globenewswire.com Cabaletta Bio to Participate in Upcoming Investor Conferences PHILADELPHIA, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies…